The use of increasingly advanced doping techniques in sports requires constant investments in new detection processes and technologies, forcing doping control laboratories to develop their innovative capability. Although WADA considers that all accredited labs should have equal quality, sports scientists point to the huge economic and cultural differences between emerging and developed countries. This article is in line with other studies that: (1) consider doping to be a biomedical technology that needs to be analysed under the lens of innovation theory; and (2) advocate the need to redesign antidrug policies to overcome the present limitations. This paper's main objective is to present a technological capability (TC) metric for anti-doping labs that can guide their technological strategy, helping them perform a more significant role in redesigning antidrug policy. The secondary objective is to report the testing of the metric at the Brazilian Doping Control Laboratory (LBCD). The construction of the analytical framework followed the recommendations for qualitative metrics. The main result was the TC metric, formulated with input from experts on doping control. Interviews revealed that the proposed metric could help laboratories better manage their R&D processes, including drug testing. The collected evidence suggests that a global network approach, including WADA requirements that consider countries' economic realities, are crucial to guide investments and prevent drug control labs from prioritising short-term profits over steady investments in R&D.